FACTORS DETERMINING THE RESPONSE FOR TREATMENT WITH MONOCLONAL ANTIBODIES TO RANKL (DENOSUMAB) IN WOMEN WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

P. S. Kovalenko; I. S. Dydykina; A. V. Smirnov; E. L. Nasonov

doi:undefined

FACTORS DETERMINING THE RESPONSE FOR TREATMENT WITH MONOCLONAL ANTIBODIES TO RANKL (DENOSUMAB) IN WOMEN WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

P. S. Kovalenko, I. S. Dydykina, A. V. Smirnov, E. L. Nasonov

Full Text:

PDF (Rus) |

Generate QR code

Keywords

Osteoporosis, treatment, denosumab

About the Authors

P. S. Kovalenko

Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation

Moscow

I. S. Dydykina

Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation

Moscow

A. V. Smirnov

Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation

Moscow

E. L. Nasonov

Research Institute of Rheumatology named after V.A. Nasonova
Russian Federation

Moscow

Review

For citations:

Kovalenko P.S., Dydykina I.S., Smirnov A.V., Nasonov E.L. FACTORS DETERMINING THE RESPONSE FOR TREATMENT WITH MONOCLONAL ANTIBODIES TO RANKL (DENOSUMAB) IN WOMEN WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS. Osteoporosis and Bone Diseases. 2020;23(2):73. (In Russ.)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)

Username
Password
	Remember me

User

Osteoporosis and Bone Diseases

FACTORS DETERMINING THE RESPONSE FOR TREATMENT WITH MONOCLONAL ANTIBODIES TO RANKL (DENOSUMAB) IN WOMEN WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

Full Text:

Keywords

About the Authors

Review

For citations:

Cookies policy